Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
ConditionHypertension
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-64
SponsorAddpharma Inc.
About this trial
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Eligibility criteria
Qualifiers
Healthy adult volunteers aged ≥19 and <65 years at the time of the screening visit
Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Disqualifiers
Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied
Trial design
Treatments tested in this trial
- Treatment A(AD-2321)
- Treatment B(AD-2322)
- Treatment C(AD-2321+AD-2322)
Treatment groups
41 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov